Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Active, not recruiting · Phase 3 · NCT04975997
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $142,493
- U.S. investigators named
- 7
- Sites paid
- 6
- Planned or actual enrollment
- 939
About the trial
- Sponsor
- Celgene
- Tested
- Dexamethasone (drug), Daratumumab (drug), Bortezomib (drug), Iberdomide (drug), Iberdomide (drug), Iberdomide (drug), Dexamethasone (drug), Daratumumab (drug)
- Dates
- Started 2022-06-23; completion 2032-06-25
- Results posted
- Not yet
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
From ClinicalTrials.gov, last updated 2026-04-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $142,493 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mohit Narang, M.D. Medical Oncology · Owing Mills, MD
- Sandeep S. Jain, MBBS Critical Care Medicine · Saint Cloud, MN
- Kruti Patel, DO Hematology & Oncology · Cincinnati, OH
- Jason M. Melear, M.D. Medical Oncology · Austin, TX
- Omer M. Ali, MD Hematology & Oncology · Hampton, VA
- Scott J. Cross, MD Specialist · Norfolk, VA
- Amanda L. Gillespie-twardy, M.D. Hematology & Oncology · Roanoke, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Virginia Oncology Associates $46,710
- Minnesota Hematology / Oncology, PA $43,627
- Maryland Oncology Hematology, PA $19,061
- Blue Ridge Cancer Care $14,015
- Texas Onco Southwest Fort Worth $13,820
- Oncology Hematology Care, Inc $5,260
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.